Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate whether a fluorescent die and a special infrared camera can assist with the identification of the important structures during laparoscopic cholecystectomy. This finding may assist surgeons to perform laparoscopic cholecystectomy in less time and in a safer fashion than standard laparoscopic cholecystectomy.


Clinical Trial Description

The purpose of this study is to evaluate whether systemically injected ICG, when fluorescing in response to NIR illumination, can assist with the identification of the CBD (common bile duct)during laparoscopic cholecystectomy. This finding may assist surgeons to perform laparoscopic cholecystectomy in less time and with less morbidity than standard laparoscopic cholecystectomy.It is expected that a successful outcome to such a trial will result in less time in the operating room and less morbidity following laparoscopic cholecystectomy.

Laparoscopic cholecystectomy is indicated for cholecystitis, biliary colic, resolved biliary pancreatitis, and symptomatic cholelithiasis. Laparoscopic cholecystectomy involves the introduction of surgical instruments through a number (usually 4) of small incisions measuring about 5-12 mm each with visual guidance being provided by means of a camera attached to an endoscope introduced through a similarly small access port. Laparoscopic techniques offer numerous benefits including a decrease in postoperative pain, some improvement in time to tolerance of food and return of bowel function, shorter hospital stay and more rapid return to normal activity.

Laparoscopic cholecystectomy is one of the most frequently performed surgical procedures in the United States. Iatrogenic bile duct injuries are a serious complication and patients undergoing the laparoscopic type of cholecystectomy are at increased risk for this complication. To minimize risk of injury, techniques such as "critical view" (dissection and visualization of the cystic duct and cystic artery) have been developed. However, adhesions, inflammation and anatomical variation can make surgical dissection and identification of significant structures difficult. In addition significantly longer operative times are seen when attempting to obtain the critical view. Some advocate the routine use of cholangiography (IOC) but the national standard of care remains to only perform IOC selectively. IOC requires cannulation of the cystic duct, injection of iodinated dye, and fluoroscopy which adds significantly to the operative time and morbidity especially in centers where routine IOC is not performed.

The present study will investigate whether the use of NIRF after injection of ICG will make identification of the Biliary structures and CBD clearer and decrease the time required to dissect out critical structures and perform safe cholecystectomy.

The SPY® Intraoperative Imaging System is cleared for use in Canada, Japan, Europe and the US. SPY was originally developed for applications in cardiac surgery and allows cardiac surgeons to visually assess bypass graft quality in real-time while the patient is still in the operating room. Subsequently, SPY has received clearance from the FDA for use in plastic and reconstructive surgery and in solid organ transplant.

The SPY Intraoperative Imaging System was originally developed for open surgical procedures using ICG, which is an FDA approved drug. ICG is a fluorescent compound, which can be administered intravenously or intra-arterially. The dye absorbs light in the near infrared (NIR) region at 806 nm, and emits light at a slightly longer wavelength, 830 nm. When injected intravenously, ICG rapidly and extensively binds to plasma proteins and is confined to the intravascular compartment with minimal leakage into the interstitium under normal conditions. ICG is taken up by the liver and then excreted into the biliary system where it can be imaged. The SPY System has been the subject of numerous peer reviewed publications demonstrating its safety .

SPY scope, the endoscopic version of SPY, is an endoscopic visible (VIS) NIR imaging system consisting of:

1. An endoscopic light source that provides illumination for visible light imaging and NIR fluorescence excitation to the endoscope via a flexible light guide

2. Rigid endoscopes optimized for illuminating the field of view and transmitting images in the visible and NIR spectrum, and

3. A high definition (HD) endoscopic camera system connected to the endoscope eyepiece and acquiring high resolution visible and NIR fluorescence images The ICG (25 mg per vial) will be reconstituted according to the manufacturer's instructions using the entire contents (10 ml) of the sterile diluent supplied, yielding a 2.5 mg/ml solution of ICG or using half of the diluent supplied (5 ml) yielding a 5 mg/ml solution.

ICG Diagnostic Procedure: 3ml of 2.5 mg/ml solution (Akorn product, US Monograph) The ICG may be administered through a peripheral venous access. Based on our prior experience in colorectal cases 1.0 ml of a 2.5 mg/ml solution of ICG (flushed with 10 ml saline) will be administered.

Our study will include patients undergoing laparoscopic cholecystectomy for both acute cholecystitis and non-acute symptomatic cholelithiasis. The standard operating technique will be used for all patients including the critical view technique and fluoroscopic IOC if clinically indicated.

Our primary endpoint will be operative time measured as the time from the beginning of the dissection until the gallbladder is separated entirely from the gall bladder fossa.

Secondary endpoints will be time to identification of structures and safety of the operation. Other endpoints such as CBD injury and postop bile leak will be included if identified. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01424215
Study type Interventional
Source Maimonides Medical Center
Contact
Status Completed
Phase N/A
Start date January 2011
Completion date August 2014

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03636841 - Reduction of Operating Time by a Smoke Electroprecipitation Device for Acute Cholecystitis N/A
Completed NCT02379780 - Ultrasound Guided Subcostal Transversus Abdominis Plane Versus Paravertebral Block in the Laparoscopic Cholecystectomy N/A
Completed NCT02264444 - Establishing Visualization Grading Scale on LESS Cholecystectomy N/A
Completed NCT01937104 - ONSD According to the Position During Laparoscopy N/A
Completed NCT02461147 - Prospective Validation of "Cholecystectomy First" Strategy for Gallstone Migration
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT00746850 - Harmonic in Laparoscopic Cholecystectomy for Acute Cholecystitis N/A
Completed NCT00940264 - Laparoscopic Transvaginal Hybrid Cholecystectomy: a Prospective Data Collection. N/A
Completed NCT00370344 - Small-incision Open Cholecystectomy or Laparoscopic Cholecystectomy for Gallbladder Disease Phase 2/Phase 3
Completed NCT00195351 - Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection Phase 4
Completed NCT02858986 - 3D Versus 4K Laparoscopic Cholecystectomy N/A
Completed NCT04602156 - US-guided Trocar Versus Seldiger Technique for Percutaneous Cholecystostomy N/A
Completed NCT04942665 - Low Dose ICG for Biliary Tract and Tumor Imaging Phase 2
Completed NCT02547064 - Effect of Modified Stylet Angulation on the Intubation With GlideScope® N/A
Completed NCT00230971 - Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI) Phase 4
Completed NCT04122261 - A Clinical Study of Chinese Domestic Surgical Robot N/A
Completed NCT04716166 - Incentive Spirometry and Upper Abdominal Laparoscopic Surgery N/A
Completed NCT01476319 - Improving Informed Consent Process for Percutaneous Cholecystostomy in the Emergency Department N/A
Withdrawn NCT02225418 - Transmuscular Quadratus Lumborum Block for Laparoscopic Cholecystectomy N/A
Suspended NCT04306939 - Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study